Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
fabry disease market insights epidemiology and market forecast

SALE

Fabry Disease - Market Insight, Epidemiology and Market Forecast - 2028

Published Date : 2019

Pages : 154

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

fabry disease market insights epidemiology and market forecast

DelveInsight's 'Fabry Disease - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Fabry Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Fabry Disease from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028

Fabry Disease - Disease Understanding and Treatment Algorithm

Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and caused by mutations in the GLA gene located in chromosome Xq22.1 and which encodes the alpha-galactosidase A (AGA) enzyme. It is a multi-systemic and a life-threatening condition which is one of the most common lysosomal storage disease after the Gaucher Disease. It is characterized by specific neurological, cutaneous, renal, cardiovascular, cochleo-vestibular and cerebrovascular manifestations.

As per the National Fabry Disease Foundation, Fabry disease is a rare genetic disorder which is caused by the deficiency of defective gene i.e. alpha-galactosidase-A gene (GLA gene) which leads to deficiency or absent activity of enzyme alpha-galactosidase A. Alpha-galactosidase A (AGA) enzyme hydrolyses the terminal ? -galactosyl moieties from glycolipids and glycoproteins. Absent or deficient activity of lysosomal exoglycohydrolase agalactosidase A (a-D-galactoside galactohydrolase),results in progressive accumulation of globotriaosylceramide (Gb3 or GL-3; also known as ceramidetrihexoside or CTH) and related glycosphingolipids (galabiosylceramide) within lysosomes which are ubiquitous subcellular organelles, in a variety of cell types, including capillary endothelial cells, renal (podocytes, tubular cells, glomerular endothelial, mesangial and intersticial cells), cardiac (cardiomyocytes and fibroblasts) and nerve cells.

The DelveInsight Fabry Disease market report gives a thorough understanding of the Fabry Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Fabry Disease in the US, Europe, and Japan.

Fabry Disease Epidemiology

The Fabry Disease epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by diagnosed prevalent population, gender-specific diagnosed prevalent population and phenotype-specific diagnosed prevalent population of Fabry Disease.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the prevalent population of Fabry Disease was estimated to be 16,800 [7MM] in 2018. United States accounts for the highest Fabry Disease cases, followed by EU5 (Germany, France, Italy, Spain and UK) and Japan. Among the EU5 countries UK had the highest prevalent patient population of Fabry Disease, followed by France.

Fabry Disease Drug Chapters

This segment of the Fabry Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, the effective management of Fabry disease requires a multidisciplinary approach. Comprehensive therapy includes intravenously administered enzyme replacement therapy (ERT) or Oral Chaperone Therapy, conventional medical treatment, and adjunct therapies, and may include lifestyle modifications and prophylactic medications. Fabrazyme (Sanofi-Genzyme); Galafold (Amicus Therapeutics) and Replagal (Shire) are the approved therapies for the treatment of Fabry disease. All these therapies are available in Europe and Japan however Replagal is withdrawn from the market in the US by the Shire in 2012. Galafold (migalastat) is a first-in-class chaperone therapy approved in the European Union as a monotherapy for Fabry disease in patients with amenable mutations. It got approved in May 2016 in Europe being developed by Amicus Therapeutics. Detailed chapters for all of these drugs have been covered in the report.

Fabry Disease Market Outlook

The Fabry Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Fabry Disease was estimated to be USD 1,211.3 million in 2018. The United States accounts for the largest market size of Fabry Disease, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

The dynamics of Fabry Disease market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Several companies are working robustly on many new therapies in Europe with novel mechanism of action; including Lucerastat (Idorsia Pharmaceuticals); Pegunigalsidase alfa (Protalix Biotherapeutics); Venglustat (Sanofi Genzyme) and AVR-RD-01 (Avrobio). The United States accounts for the largest market size of Fabry Disease, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan

Fabry Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The market size of Fabry Disease includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.

To counter current unmet needs of the market and to provide better treatment options for Fabry Disease, several companies are working robustly on developing new therapies with novel mechanism of action; including Lucerastat (Idorsia Pharmaceuticals); Pegunigalsidase alfa (Protalix Biotherapeutics); Venglustat (Sanofi Genzyme) and AVR-RD-01 (Avrobio) which are expected to enter Fabry Disease market by 2028.

Lucerastat is a small molecule called an “iminosugar,” developed by Idorsia Pharmaceuticals for the treatment of Fabry Disease. It funtions as a substrate reduction therapy. The company is currently leading a pivotal Phase III study, which is being designed to assess the effects of lucerastat on neuropathic pain and gastrointestinal symptoms, as well as safety and tolerability, in patients with Fabry disease.

Pegunigalsidase alfa (PRX-102) is a novel, PEGylated, chemically modified, ?-galactosidase A enzyme replacement therapy developed by Protalix BioTherapeutics. It is currently in Phase III stage of development for the treatment of Fabry Disease.

Fabry Disease Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Fabry Disease Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Fabry Disease Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Fabry Disease market.

• Organize sales and marketing efforts by identifying the best opportunities for Fabry Disease market.

• To understand the future market competition in the Fabry Disease market.

1 Key Insights

2 Fabry Disease Market Overview at a Glance

2.1 Market Share (%) Distribution of Fabry Disease in 2017

2.2 Market Share (%) Distribution of Fabry Disease in 2028

3 Disease Background and Overview

3.1 Introduction

3.2 Classification

3.3 Signs and Symptoms

3.4 Etiology

3.5 Inheritance Pattern

3.6 Genetics

3.7 Pathogenesis

3.8 Molecular Basis

3.9 Diagnosis

3.1 European Fabry Working Group (EFWG): Diagnostic criteria

3.11 Challenges in Diagnosis

3.12 Diagnosis Algorithm for Fabry Disease

4 Epidemiology and Patient Population

4.1 Key Findings

5 7MM Total Prevalent Patient Population of Fabry Disease

6 Country Wise-Epidemiology of Fabry Disease

6.1 United States

6.1.1 Assumptions and Rationale

6.1.2 Prevalent Cases of Fabry Disease in the United States

6.1.3 Gender Specific Diagnosed Prevalent cases of Fabry Disease in the United States

6.1.4 Phenotype Specific Prevalent Cases of Fabry Disease in the United States

6.1.5 Phenotype Specific Diagnosed Prevalent Cases of Fabry Disease in the United States

6.2 EU5

6.2.1 Assumptions and Rationale

6.3 Germany

6.3.1 Prevalent Cases of Fabry Disease in Germany

6.3.2 Gender Specific Prevalent cases of Fabry Disease in Germany

6.3.3 Phenotype-Specific Prevalent Cases of Fabry Disease in Germany

6.3.4 Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Germany

6.4 France

6.4.1 Prevalent Cases of Fabry Disease in France

6.4.2 Gender Specific Prevalent cases of Fabry Disease in France

6.4.3 Phenotype-Specific Prevalent Cases of Fabry Disease in France

6.4.4 Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in France

6.5 Italy

6.5.1 Prevalent Cases of Fabry Disease in Italy

6.5.2 Gender Specific Prevalent cases of Fabry Disease in Italy

6.5.3 Phenotype-Specific Prevalent Cases of Fabry Disease in Italy

6.5.4 Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Italy

6.6 Spain

6.6.1 Prevalent Cases of Fabry Disease in Spain

6.6.2 Gender Specific Prevalent cases of Fabry Disease in Spain

6.6.3 Phenotype-Specific Prevalent Cases of Fabry Disease in Spain

6.6.4 Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Spain

6.7 United Kingdom

6.7.1 Prevalent Cases of Fabry Disease in the United Kingdom

6.7.2 Gender Specific Prevalent cases of Fabry Disease in the United Kingdom

6.7.3 Phenotype-Specific Prevalent Cases of Fabry Disease in the United Kingdom

6.7.4 Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in the United Kingdom

6.8 Japan

6.8.1 Assumptions and Rationale

6.8.2 Prevalent Cases of Fabry Disease in Japan

6.8.3 Gender Specific Prevalent cases of Fabry Disease in Japan

6.8.4 Phenotype-Specific Prevalent Cases of Fabry Disease in Japan

6.8.5 Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Japan

7 Treatment and Management of Fabry Disease

7.1 Guidelines for management of Fabry Disease

7.2 Croatian Society: Recommendation for the treatment of Fabry Disease

7.3 Treatment Practices

8 Treatment Algorithm

9 Unmet Needs

10 Marketed Drugs

10.1 Galafold: Amicus Therapeutics

10.1.1 Drug Description

10.1.2 Regulatory Milestones

10.1.3 Other Developmental Activities

10.1.4 Safety and Efficacy

10.1.5 Product Profile

10.2 Replagal: Shire

10.2.1 Drug Description

10.2.2 Regulatory Milestones

10.2.3 Other Developmental Activities

10.2.4 Safety and Efficacy

10.2.5 Product Profile

10.3 Fabrazyme: Genzyme

10.3.1 Product Description

10.3.2 Regulatory Milestones

10.3.3 Other Developmental Activities

10.3.4 Safety and Efficacy

10.3.5 Product Profile

11 Emerging Therapies

11.1 Key cross competition- Emerging Therapies

11.2 Lucerastat: Idorsia Pharmaceuticals

11.2.1 Product Description

11.2.2 Other Development Activities

11.2.3 Clinical Development

11.2.4 Safety and Efficacy

11.2.5 Product Profile

11.3 Pegunigalsidase alfa: Protalix Biotherapeutics

11.3.1 Product Description

11.3.2 Other Development Activities

11.3.3 Clinical Development

11.3.4 Safety and Efficacy

11.3.5 Product Profile

11.4 AVR-RD-01: Avrobio

11.4.1 Product Description

11.4.2 Other Development Activities

11.4.3 Clinical Development

11.4.4 Product Profile

11.5 Venglustat: Sanofi Genzyme

11.5.1 Product Description

11.5.2 Other Development Activities

11.5.3 Clinical Development

11.5.4 Product Profile

12 Fabry Disease: 7 Major Market Analysis

12.1 Key Findings

12.2 Market Size of Fabry Disease in 7MM

13 Market Outlook by Country

14 The United States: Market Outlook

14.1 United States Market Size

14.1.1 Total Market Size of Fabry Disease

14.1.2 Market Size of Fabry Disease by Therapies

15 EU-5 Countries: Market Outlook

15.1 Germany

15.1.1 Total Market size of Fabry Disease

15.1.2 Market Size of Fabry Disease by Therapies

15.2 France

15.2.1 Total Market Size of Fabry Disease

15.2.2 Market Size of Fabry Disease by Therapies

15.3 Italy

15.3.1 Total Market Size of Fabry Disease

15.3.2 Market Size of Fabry Disease by Therapies

15.4 Spain

15.4.1 Total Market Size of Fabry Disease

15.4.2 Market Size of Fabry Disease by Therapies

15.5 United Kingdom

15.5.1 Total Market Size of Fabry Disease

15.5.2 Market Size of Fabry Disease by Therapies

15.6 Japan: Market Outlook

15.6.1 Total Market Size of Fabry Disease

15.6.2 Market Size of Fabry Disease by Therapies

16 Market Drivers

17 Market Barriers

18 Appendix

18.1 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

List of Tables:

Table 1: Pathophysiologic findings in Anderson-Fabry Disease

Table 2: Proposed assessments for Fabry Disease

Table 3: Clinical evaluation and monitoring of adult patients with Fabry Disease

Table 4: Clinical evaluation and monitoring of pediatric patients with Fabry Disease

Table 5: Diagnostic criteria of European Fabry Working Group (EFWG)

Table 6: Fabry disease: Common misdiagnoses

Table 7: Prevalent Patient Population of Fabry Disease in 7MM (2017-2028)

Table 8: Prevalent Cases of Fabry Disease in the United States (2017-2028)

Table 9: Gender Specific Prevalent Cases of Fabry Disease in the United States (2017-2028)

Table 10: Phenotype Specific Prevalent Cases of Fabry Disease in the United States (2017-2028)

Table 11: Phenotype Specific Diagnosed Prevalent Cases of Fabry Disease in the United States (2017-2028)

Table 12: Prevalent Cases of Fabry Disease in Germany (2017-2028)

Table 13: Gender Specific Prevalent Cases of Fabry Disease in Germany (2017-2028)

Table 14: Phenotype-Specific Prevalent Cases of Fabry Disease in Germany (2017-2028)

Table 15: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Germany (2017-2028)

Table 16: Diagnosed Prevalent Cases of Fabry Disease in France (2017-2028)

Table 17: Gender Specific Prevalent Cases of Fabry Disease in France (2017-2028)

Table 18: Phenotype-Specific Prevalent Cases of Fabry Disease in France (2017-2028)

Table 19: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in France (2017-2028)

Table 20: Prevalent Cases of Fabry Disease in Italy (2017-2028)

Table 21: Gender Specific Prevalent Cases of Fabry Disease in Italy (2017-2028)

Table 22: Phenotype-Specific Prevalent Cases of Fabry Disease in Italy (2017-2028)

Table 23: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Italy (2017-2028)

Table 24: Prevalent Cases of Fabry Disease in Spain (2017-2028)

Table 25: Gender Specific Prevalent Cases of Fabry Disease in Spain (2017-2028)

Table 26: Phenotype-Specific Prevalent Cases of Fabry Disease in Spain (2017-2028)

Table 27: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Spain (2017-2028)

Table 28: Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Table 29: Gender Specific Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Table 30: Phenotype-Specific Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Table 31: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Table 32: Prevalent Cases of Fabry Disease in Japan (2017-2028)

Table 33: Gender Specific Prevalent Cases of Fabry Disease in Japan (2017-2028)

Table 34: Phenotype-Specific Prevalent Cases of Fabry Disease in Japan (2017-2028)

Table 35: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Japan (2017-2028)

Table 36: Current guidelines for instituting enzyme replacement therapy in Fabry Disease patients

Table 37: Adjunctive therapies and preventive measures in Fabry Disease patients for common Fabry related morbidities

Table 38: Implications for Recommendations

Table 39: Treatment goals for Fabry Disease patients associated with other conditions

Table 40: Effect of enzyme replacement therapy on signs and Symptoms of Fabry Disease

Table 41: Enzyme Replacement Therapy

Table 42:Recommended analgesic drugs for supportive treatment of Chronic neuropathic pain in Fabry Disease

Table 43: Recommended analgesic drugs for supportive treatment of acute pain in Fabry Disease

Table 44: Patent Details: Migalastat

Table 45: Galafold, Clinical Trial Description, 2019

Table 46: Patent Details: Replagal

Table 47: Replagal, Clinical Trial Description, 2019

Table 48: Patent Details: Fabrazyme

Table 49: Key cross competition - Emerging Therapies

Table 50: Lucerastat, Clinical Trial Description, 2018

Table 51: Pegunigalsidase alfa, Clinical Trial Description, 2019

Table 52: AVR-RD-01 Clinical Trial Description, 2019

Table 53: Venglustat, Clinical Trial Description, 2019

Table 54: 7 Major Market Size of Fabry Disease in USD Million (2017-2028)

Table 55: United States Market Size of Fabry Disease in USD Million (2017-2028)

Table 56: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Table 57: Germany Market Size of Fabry Disease in USD Million (2017-2028)

Table 58: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Table 59: France Market Size of Fabry Disease in USD Million (2017-2028)

Table 60: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Table 61: Italy Market Size of Fabry Disease in USD Million (2017-2028)

Table 62: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Table 63: Spain Market Size of Fabry Disease in USD Million (2017-2028)

Table 64: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Table 65: United Kingdom Market Size of Fabry Disease in USD Million (2017-2028)

Table 66: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Table 67: Japan Market Size of Fabry Disease in USD Million (2017-2028)

Table 68: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

List of Figures:

Figure 1: Characteristics of Type 1 classic and Type 2 later-onset Anderson-Fabry Disease

Figure 2: Symptoms of Fabry Disease in Adults, Childhood and Adolescence

Figure 3: Progression of clinical findings in Fabry's disease with age

Figure 4: Role of a-galactosidase A in GL-3 catabolism

Figure 5: Inheritance Pattern of Fabry Disease

Figure 6: Genetic and molecular basis of Anderson-Fabry Disease

Figure 7: ?-galactosidase A gene mutations

Figure 8: Diagnosis Algorithm for Anderson-Fabry Disease

Figure 9: Prevalent Patient Population of Fabry Disease in 7MM (2017-2028)

Figure 10: Prevalent Cases of Fabry Disease in the United States (2017-2028)

Figure 11: Gender Specific Prevalent Cases of Fabry Disease in the United States (2017-2028)

Figure 12: Phenotype Specific Prevalent Cases of Fabry Disease in the United States (2017-2028)

Figure 13: Phenotype Specific Diagnosed Prevalent Cases of Fabry Disease in the United States (2017-2028)

Figure 14: Prevalent Cases of Fabry Disease in Germany (2017-2028)

Figure 15: Gender Specific Prevalent Cases of Fabry Disease in Germany (2017-2028)

Figure 16: Phenotype-Specific Prevalent Cases of Fabry Disease in Germany (2017-2028)

Figure 17: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Germany (2017-2028)

Figure 18: Diagnosed Prevalent Cases of Fabry Disease in France (2017-2028)

Figure 19: Gender Specific Prevalent Cases of Fabry Disease in France (2017-2028)

Figure 20: Phenotype-Specific Prevalent Cases of Fabry Disease in France (2017-2028)

Figure 21: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in France (2017-2028)

Figure 22: Prevalent Cases of Fabry Disease in Italy (2017-2028)

Figure 23: Gender Specific Prevalent Cases of Fabry Disease in Italy (2017-2028)

Figure 24: Phenotype-Specific Prevalent Cases of Fabry Disease in Italy (2017-2028)

Figure 25: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Italy (2017-2028)

Figure 26: Prevalent Cases of Fabry Disease in Spain (2017-2028)

Figure 27: Gender Specific Prevalent Cases of Fabry Disease in Spain (2017-2028)

Figure 28: Phenotype-Specific Prevalent Cases of Fabry Disease in Spain (2017-2028)

Figure 29: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Spain (2017-2028)

Figure 30: Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Figure 31: Gender Specific Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Figure 32: Phenotype-Specific Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Figure 33: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in the United Kingdom (2017-2028)

Figure 34: Prevalent Cases of Fabry Disease in Japan (2017-2028)

Figure 35: Gender Specific Prevalent Cases of Fabry Disease in Japan (2017-2028)

Figure 36: Phenotype-Specific Prevalent Cases of Fabry Disease in Japan (2017-2028)

Figure 37: Phenotype-Specific Diagnosed Prevalent Cases of Fabry Disease in Japan (2017-2028)

Figure 38: Treatment Algorithm for Anderson-Fabry Disease

Figure 39: Unmet Needs of Fabry Disease

Figure 40: 7 Major Market Size of Fabry Disease in USD Million (2017-2028)

Figure 41: Market Size of Fabry Disease in the United States, USD Million (2017-2028)

Figure 42: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Figure 43: Market Size of Fabry Disease in Germany, USD Million (2017-2028)

Figure 44: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Figure 45: Market Size of Fabry Disease in France USD Million (2017-2028)

Figure 46: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Figure 47: Market Size of Fabry Disease in Italy, USD Million (2017-2028)

Figure 48: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Figure 49: Market Size of Fabry Disease in Spain, USD Million (2017-2028)

Figure 50: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Figure 51: Market Size of Fabry Disease in the United Kingdom, USD Million (2017-2028)

Figure 52: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Figure 53: Market Size of Fabry Disease in Japan, USD Million (2017-2028)

Figure 54: Market Size of Fabry Disease by Therapies in USD Million (2017-2028)

Figure 55: Market Drivers

Figure 56: Market Barriers

Tags:

License Type

Offer